Additionally, if Australia is going to the location for all or part of the P2/3, then Dr. Mac needs to be speaking out to recruit participants, especially if there is to be a Donepezil-naive group, which as Xena points out will be more difficult to recruit.
IMO - The lack of transparency that burns me is that there was no emphasis on the fact that the combo treatment would have poorer results than the 2-73 only results. That has been known for a while and it could have been noted at the ASM as the keenest interest of investors has been in how well does 2-73 perform. This silence thing implies a fear and inability to communicate in a proactive manner.
But instead, we receive language stating no perceived difference between the two. "Com'n on!" It appears that management thought the combo treatment would yield better results than 2-73 alone and were surprised when the opposite was true and it did not know how to respond/react.
News 
Market Data 
Discover 
AI
